CRC
NBIX icon

Curi RMB Capital’s Neurocrine Biosciences NBIX Stock Holding History

Curi RMB Capital’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,327
Closed -$438K – 960
2026
Q1 		$438K Sell
3,327
-907
-21% -$120K 0.01% 638
2025
Q4 		$601K Buy
+4,234
New +$613K 0.01% 562
2019
Q1 		– Sell
-22,416
Closed -$1.6M – 886
2018
Q4 		$1.6M Sell
22,416
-18
-0.1% -$1.73K 0.04% 400
2018
Q3 		$2.76M Sell
22,434
-3,631
-14% -$412K 0.07% 313
2018
Q2 		$2.56M Sell
26,065
-12,868
-33% -$1.15M 0.06% 329
2018
Q1 		$3.23M Sell
38,933
-18,344
-32% -$1.55M 0.08% 307
2017
Q4 		$4.44M Sell
57,277
-5,775
-9% -$394K 0.12% 244
2017
Q3 		$3.86M Buy
63,052
+13,590
+27% +$717K 0.1% 282
2017
Q2 		$2.27M Buy
+49,462
New +$2.4M 0.07% 352

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Curi RMB Capital's NBIX Position: Q2 2026 in Review

Curi RMB Capital sold out of Neurocrine Biosciences (NBIX) in Q2 2026, closing a stake of 3,327 shares — an estimated $438K sold.

Curi RMB Capital first reported a position in NBIX in Q2 2017 and held it in 9 quarters. The position peaked at $4.44M in Q4 2017. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Curi RMB Capital reported no remaining Neurocrine Biosciences position as of Q2 2026 after selling out during the quarter.
  • Curi RMB Capital sold 3,327 Neurocrine Biosciences shares in Q2 2026, an estimated $438K.
  • Curi RMB Capital first reported a position in Neurocrine Biosciences in Q2 2017 and held it in 9 quarters.
  • Curi RMB Capital's Neurocrine Biosciences position peaked at $4.44M in Q4 2017.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Curi RMB Capital's 13F filing for Q2 2026, filed 14 Aug 2026.